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Summary Studies with a conjugate of carboxypeptidase G2 (CPG2) and the F(ab')2 fragment of monoclonal
anti-CEA antibody, A5B7, have shown specific localisation in a human colon tumour xenograft, LS174T,
growing in nude mice. The conjugate reaches a peak concentration in the tumour within 24 h but enzyme
activity in blood remains above a critical value for therapeutic purposes for several days. Here we describe a
new monoclonal antibody, SB43, raised against CPG2 which is capable of reducing enzyme activity in blood.
In vitro studies demonstrated specific binding of SB43 to CPG2 causing inactivation. Moreover, in the nude
mouse model SB43 was also capable of inactivating the enzyme in the circulation within minutes of
administration. Radiolabelled native SB43 persisted in blood for several days and appreciable non-specific
uptake into the xenograft was also observed. Uptake of SB43 by the tumour, with possible inactivation of
CPG2 at this site, could be limited by first coupling the antibody to galactose. This ensured recognition and
excretion of SB43 and SB43-enzyme complexes via the liver and their rapid removal from the circulation.
Galactosylation had no effect on the ability of SB43 to inactivate the enzyme.
Anti-cancer agents such as drugs, toxins and radioisotopes
have been linked directly to antibodies to achieve greater
anti-tumour selectivity but this approach has so far proved to
be of restricted therapeutic value. Major limitations resulting
from the use of directly coupled antibodies are the amount of
anti-cancer agent that can be attached to the antibody mole-
cule without loss of immunological activity and the amount
of conjugate that can be specifically targeted to tumour. A
novel approach of converting a prodrug into a potent anti-
cancer agent by a targeted enzyme (ADEPT) aims to over-
come these difficulties. As originally envisaged (Bagshawe,
1987) this system employed two phases in which an enzyme
conjugated to an anti-tumour antibody was first allowed to
localise and clear from the circulation before injection of the
prodrug. Our preliminary studies (Bagshawe et al., 1988)
were carried out with carboxypeptidase G2 (CPG2), a folate
depleting bacterial enzyme, conjugated to the F(ab')2 frag-
ment of a monoclonal anti-hCG antibody and capable of
converting a glutamyl benzoic acid mustard prodrug into a
potent benzoic acid mustard. In the choriocarcinoma xeno-
graft system tested, the target antigen, hCG, was present in
the plasma and clearance of the antibody-enzyme conjugate
from the circulation occurred within 72 h allowing administ-
ration of the prodrug and elimination of the tumour. A
similar approach, in which placental alkaline phosphatase
was used to convert the prodrug etoposide phosphate into
etoposide, was shown to be effective in a colon xenograft
model (Senter et al., 1988). We have now extended our
studies to the human colonic carcinoma xenograft model
(LS174T) in which we have targeted CPG2 conjugated to the
monoclonal antibody fragment, A5B7-F(ab')2, directed at
carcinoembryonic antigen (CEA). A5B7-F(ab')2-CPG2 local-
ised in LS174T xenografts but enzyme activity persisted in
blood for 5-6 days after administration of the conjugate.
Injection of prodrug while enzyme activity remained in blood
was found to be toxic and potentially lethal. Therefore, to
achieve a maximum therapeutic effect, it was considered to
be advantageous to accelerate the clearance of enzyme activ-
ity from blood while maintaining peak levels in the tumour.
Studies reported here employ a new monoclonal antibody
(SB43) raised against CPG2 which binds to the enzyme and
inhibits its activity. Such an antibody, when deployed in vivo,
has the potential to inactivate enzyme localised at tumour
sites as well as enzyme in plasma. One method of minimising
this is to couple galactose to the antibody so that it may be
rapidly removed from blood by hepatic lectin receptors
(Thornburg et al., 1980). This study describes the preparation
of native and galactosylated SB43 and its effect on blood
clearance and tumour localisation of A5B7-F(ab')2-CPG2 in
the LS174T model.
Materials and methods
Carboxypeptidase G2 (CPG2), a folate depleting enzyme of
bacterial origin, which catalyses the hydrolytic cleavage of
reduced and non reduced folates, was produced by the Div-
ision of Biotechnology at Porton Down as described by
Sherwood et al. (1985).
SB43, an IgGI monoclonal antibody, was raised against
CPG2 as follows: Balb/C mice (6-8 weeks old) were immu-
nised with 50 1tg CPG2 i.p. in incomplete Freund's adjuvant
followed by two injections of CPG2 in complete Freund's
adjuvant (50 ,g CPG2 each, i.p.) at monthly intervals and
with two daily injections (50 ig and 100 Lg in PBS, i.v.) 2
days before fusion. Immune spleen cells were fused with
non-immunoglobulin secreting SP2/0 myeloma cells accord-
ing to the hybridoma procedures of Kohler and Milstein
(1975).
The presence of anti-CPG2 antibodies was detected by a
solid-phase indirect radioimmunoassay. A 1 iLg ml-' solution
of CPG2 in 0.05 M phosphate buffer was placed in polyvinyl
microtitre plates (100 ng per well), allowed to dry, fixed with
methanol and washed with PBS buffer containing a 0.05%
Tween and 0.1% bovine serum albumin. Supernatant or
purified antibody samples were diluted in PBS and incubated
in the CPG2 coated microtitre plates (100 ,Al per well) at 37°C
for 4 h and then for I h with 1251I-labelled rabbit anti-mouse
IgG. The wells were washed three times with PBS-Tween
buffer between each stage and after final washing individual
wells were cut and counted in a gamma counter.
The catalytic activity of native and conjugated CPG2, with
and without a 5 min prior incubation at 37°C with SB43 or
SB43-galactose (see below), was measured by a spectrophoto-
metric assay at 37'C in Tris-HCI buffer (pH 7.3, 900ILl)
containing 0.2 mM ZnC12, using 0.06 mM methotrexate
(100fil) as substrate. The reaction was started by adding
native or conjugated CPG2 (10 l) and followed by measur-
ing the decrease in absorbance at 320 nm (McCulloch et al.,
1971; Hughes et al., 1982).
CPG2 was covalently linked to the F(ab')2 fragment of the
anti-CEA antibody A5B7 by a stable thioether bond by
reacting the fragment with S-acetylthioglycolic acid N-hy-
droxysuccinimide ester (Duncan et al., 1983) and CPG2 with
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4-(p-maleimidophenyl) butyric acid N-hydroxysuccinimide es-
ter. The fragment and enzyme derivatives were mixed and
concentrated 10-fold and the conjugate purified by gel filtra-
tion (S-12 column) on FPLC (Pharmacia). Enzyme activity
was determined by the spectrophotometric assay before use.
SB43, was galactosylated according to a modification of
the method by Mattes (1987). Cyanomethyl 2, 3, 4, 6-tetra-o-
acetyl-l-thio-p-D-galactopyranoside (400 mg) in anhydrous
methanol (10 ml) was treated with 5.4 mg of sodium methox-
ide in 1 ml of anhydrous methanol at room temperature for
48 h. A stock solution of SB43 (1.3 mg ml-') was prepared in
0.25 M sodium borate buffer, pH 8.5. An aliquot of the
activated galactose derivative (101il of derivative for 200pg
SB43) was dispensed into a 3 ml glass ampoule and evapor-
ated to a glassy residue in a stream ofnitrogen. A solution of
SB43 was added and the mixture was shaken until the resi-
due dissolved. After 2 h at room temperature the solution
was dialysed against three changes of PBS.
SB43, SB43-galactose and A5B7-F(ab')2-CPG2 were label-
led with iodine-125 by the chloramine T method.
In vivo studies were carried out in nude mice bearing the
human colon adenocarcinoma xenograft, LS174T, using tu-
mours of between 500 and 700 mg. This model expresses
CEA but the plasma concentration is usually less than
5 ng ml-' for tumours less than 1 g (Philben et al., 1986).
Typically, mice were administered (i.v.) radiolabelled
antibody (SB43, 20fig) or conjugate (25 units, 150jig),
groups of four were killed at various time points after injec-
tion, and tumour and normal tissues were excised for
weighing and isotope counting. The results were expressed as
percentage of the injected dose per gram of tissue.
Measurements of enzyme clearance were made by assaying
blood samples obtained from mice injected with unlabelled
conjugate.
Results
In vitro studies
Both native and galactosylated SB43 bound to CPG2 as
tested on the solid phase indirect radioimmunoassay. Pre-
incubation of A5B7 F(ab')2-CPG2 for 5 min with SB43
resulted in a loss of enzymic activity (Figure 1) while pre-
incubation of the conjugate with an equivalent amount of
either anti-mouse IgG or the mouse monoclonal anti-hCG
antibody (SB10) did not reduce the enzymic activity of
CPG2.
In vivo studies
The biodistribution of 1251 SB43 and '25I SB43-galactose was
compared in LS174T xenografts following intravenous injec-
tion (Figure 2). The data show a greater than 10-fold de-
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Figure 2 Mice bearing LS174T xenografts were injected (i.v.)
with 20 Lg of '25l-SB43 or 1251-SB43 galactose. After 6, 24 and
48 h blood and tumour were collected and the concentration of
label determined as percentage injected dose per gram of tissue.
'251-SB43 (blood 0, tumour A). '251I-SB43 galactose (blood 0,
tumour A).
crease in blood level of galactosylated antibody in com-
parison with the native antibody and a 5-fold decrease in
percentage of injected dose per gram retained non-specifically
in the tumour 6 h after injection. By 24 h, there was almost
complete clearance of galactosylated SB43 from blood and
retention in tumour was below 0.02% compared to 5-6%
ID g-' with native SB43.
The plasma concentration of A5B7 F(ab')2-CPG2 at vari-
ous time points after i.v. administration and measured as
enzymic activity is shown in Figure 3a. Enzyme was still
detectable in blood (0.3 units ml-') after 6 days. When SB43
was injected in excess (10 times the equivalent weight of
enzyme measured in blood), 24 h after the conjugate, enzyme
activity in plasma fell to below 0.1 units ml-' within 15 min
following the SB43 injection (Figure 3b).
The effect of SB43-galactose on clearance from the blood
and localisation of '25I-A5B7-F(ab')2-CPG2 is shown in Fig-
ure 4. The radiolabelled conjugate localised in the LS174T
xenograft reaching a concentration approaching 2% of the
administered dose per gram at 24 h but gradually decreased
to below 1% by 7 days. Although a favourable tumour to
blood ratio was seen as early as 24 h after administration,
there were still 0.36 units ml-' active enzyme in plasma at
72 h. When SB43-galactose was injected 19 h after the 12511
conjugate the percentage of injected dose of the latter per
gram of tumour remained almost unaltered (Figure 4). How-
ever, there was a greater than 2-fold decrease in the concent-
ration of conjugate in the blood at 24 h after injection.
Mice injected with SB43-galactose showed higher tumour
to blood ratios at all time points studied (Figure 5) but there
was a higher uptake of radiolabelled conjugate in the liver
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Figure 1 Effect of SB43 on enzyme activity of A5B7-F(ab')2-
CPG2 as measured by the spectrophotometric assay. SB43 (0),
SBIO (U), rabbit anti-mouse IgG (A).
Figure 3 Effect of SB43 on plasma clearance of enzyme activity
in nude mice bearing LS174T xenografts after admininstration
(i.v.) of A5B7-F(ab')2-CPG2 (90 units of enzyme per mouse). a,
Mice received conjugate followed 24 h later by saline (0.2 ml i.v.).
b, Mice received conjugate followed 24 h later by 2001tg of SB43
(0.2ml i.v.).
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Figure 4 Effect of SB43 galactose on clearance and localisation
of '25I-A5B7-F(ab')2-CPG2 in mice bearing LS174T xenografts.
Mice received conjugate (25 units of enzyme per mouse) and
tumour (A) and blood (0) taken at 24, 48, 72 and 168 h after
the conjugate injection. In another group of mice SB43 galactose
(200 fig per mouse) was injected 19 h after the conjugate and
tumour (A) and blood (0) collected as before.
and therefore a lower tumour to liver ratio during the first
24 h (Figure 5a, b, c). Tumour to lung ratios were higher at
all time points studied.
Discussion
A5B7-F(ab')2-CPG2 labelled with iodine-125 localises in
LSl74T xenografts within 24 h of injection. The percentage
of the administered dose of conjugate in the tumour at 24 h
was found to be dose dependent varying from about 4%
ID g-' when 20 fig was injected to about 2% with higher
doses of 150 pg (unpublished data). Although these levels are
approximately half those obtained using unconjugated
F(ab')2 fragment and five times less than those achieved with
intact A5B7, it was nevertheless possible to achieve higher
absolute levels of localised enzyme, compatible with current
therapy experiments, by increasing the dose of conjugate
while maintaining adequate tumour to blood ratios with
SB43 aided clearance. In preliminary therapy studies (paper
in preparation) we have used doses of conjugate equivalent
to 25 units of enzyme activity, which corresponds to 150ytg
of F(ab')2. At this dosage the rate of clearance of conjugated
enzyme activity from blood, which tends to be somewhat
slower than that reported for unconjugated antibody frag-
ment alone (Rogers et al., 1986; Buchegger et al., 1983), may
result from a very low level of circulating CEA ( <Sng ml-';
Philben et al., 1986) in this model. Complexes formed in an
antigen excess would tend to be cleared more rapidly from
the circulation by the reticulo-endothelial system. The latter
situation, however, may be typical of many potential clinical
applications where patients have a high blood CEA level.
In the mouse model studied, enzyme activity of CPG2
conjugated to A5B7 F(ab')2 persisted in blood for several
days at a level which would result in conversion of prodrug
with toxic effects. A safe level of enzyme in blood (<0.3
units ml-') is reached by 6 days when the level of conjugate
in the tumour is about half of its value at 24 h. In order to
make best use of the enzyme localised at the tumour site,
clearance of enzyme from the circulation needs to be accel-
erated while keeping the tumour level unaltered.
In this study we have developed SB43, a monoclonal
antibody which, in its native or galactosylated form, selec-
tively inactivates CPG2 conjugates within minutes after injec-
tion. However, studies with 251I-labelled native SB43 have
shown it to persist in the circulation at high levels for up to
several days, resulting in a high non-specific uptake into
LS174T xenografts. This could have the disadvantage of
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Figure 5 Tumour: organ ratios obtained with "I5-A5B7-F(ab')2-
CPG2 and the effect of SB43 galactose. No SB43-galactose
( ), with SB43-galactose ( 1 ).
inactivating enzyme at the tumour site as well as in plasma.
It is necessary, therefore, to restrict the inactivating antibody,
SB43, from crossing the capillary endothelial membrane at
the tumour site. We have achieved this' by chemical
modification of SB43 such that it clears from the circulation
sufficiently rapidly to minimise non-specific uptake by
tumour.
Since SB43 inactivates plasma CPG2 within minutes after
injection, we have coupled it to cyanomethyl galactose (Mat-
tes, 1987) which allows for immune complexes formed in
antibody excess to be removed very rapidly from the circula-
tion by the galactose-specific receptors in hepatic paren-
chymal cells (Thornburg et al., 1980). By applying galac-
tosylated SB43 we have been able to inactivate plasma'CPG2
and accelerate clearance of 1251-labelled CPG2 conjugates
from blood without appreciably affecting enzyme levels in the
tumour. This has since been confirmed by measurements on
localised active enzyme concentrations in excised tumours by
in vitro turnover of prodrug (to be reported elsewhere). SB43
and its galactosylated derivative were also shown to be
effective at accelerating plasma clearance and inactivating
intact A5B7 conjugated carboxypeptidase G2.
The data presented here indicate that inactivation of the
enzyme is very rapid and is probably more important than
the clearance effect in reducing prodrug conversion in the
blood. The mechanism of inactivation by SB43 may involve
its binding at or near the active site of the enzyme or at a
distant site causing a conformational change in the enzyme
and loss of its biological activity.
The experiments described in this study are part of Our
continuing investigation into antibody directed enzyme pro-
drug therapy (ADEPT) in which: (1) antibody enzyme con-
jugate is allowed to achieve maximum localisation; (2) selec-
tive inactivation and clearance of enzyme from plasma is
achieved by the galactosylated 'clearing' antibody; (3) pro-
drugs may be injected when enzyme conjugate at the tumour
site is at its peak.
The three phase approach has several potential advantages
in that by inactivating enzyme in blood, prodrugs can be
safely administered while the tumour maintains a high con-
centration of active enzyme. Galactosylation of the 'clearing'
antibody allows accelerated clearance from blood of com-
plexed enzyme conjugate and, moreover, ensures that any
uncomplexed SB43, which could otherwise inactivate enzyme
localised at the tumour site, is also cleared. Use of the
galactosylated 'clearing' antibody should enable the whole
cycle of conjugate and prodrug to be repeated more fre-
quently to achieve an enhanced therapeutic effect.
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